Pfizer, Inc. · NYSE:PFE
Pfizer — Cowen and Company 28th Annual Health Care Conference (March 2008)
32 slides from Pfizer's conference presentation, Mar 17, 2008
Slide 1: Our Path Forward
Our Path Forward Joe Feczko Senior Vice President & Chief Medical Officer
Slide 2: Forward-Looking Statements
Forward-Looking Statements Our discussions at this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward- looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2007 Annual Report on
Slide 3: The Forces at Work in Healthcare Today
The Forces at Work in Healthcare Today s in ng S oc iety in a nc e Agi World u nd Adv ology e lop e d Pr of o e c hn De v n ce a nd T Risi Sci e ng M in D iddle Info eve Clas Reg lo p s Exp rmatio ions ing l n New osion & Med ia er ism Health US n s um ca Conso re Plans Co lidatin g Shift in Who “ O
Slide 4: Key Strategies
5 Key Strategies Refocus and Optimize the Patent- protected Portfolio Instill a Find New Culture of Opportunities Innovation and for Continuous Established Improvement Products Invest in Grow in Complementary Emerging Businesses Markets
Slide 5: Key Strategies
5 Key Strategies Refocus and Optimize the Patent- protected Portfolio Instill a Find New Culture of Opportunities Innovation and for Continuous Established Improvement Products Invest in Grow in Complementary Emerging Businesses Markets
Slide 6: Disease Area Priorities: Invest to Win
Disease Area Priorities Invest to Win First or High Market High Best in Class Growth Unmet Need 9 9 9 Oncology Pain Immunology / Inflammation Diabetes / Obesity Alzheimer’s Disease Schizophrenia
Slide 7: Today's Phase 3 Portfolio
Today’s Phase 3 Portfolio axitinib – Pancreatic Cancer PD-332334 – GAD tremelimumab – Melanoma S,S-reboxetine – Fibromyalgia NMEs apixaban – VTE Prevention Zithromax/chloroquine – Malaria CP-945598 – Obesity New Indications apixaban – Atrial Fibrillation /
Slide 8: Projected 15–20 Phase 3 Starts 2008–2009
Projected 15–20 Phase 3 Starts 2008–2009 PF-3187207 PF-885706 – GERD PF-868554 PF-734200 – Glaucoma – HCV – Diabetes PF-299804 – Cancer CP-751871 PF-4194471 PF-4522625 – Lung Cancer PH-797804 – RA – HIV – Seasonal Flu NMEs PF-4383119 IV sulopenem/Oral CP-690550 UK-453061 –
Slide 9: Potential New Indications Expected To Drive Value
Potential New Indications Expected To Drive Value Colorectal es nu ve Non Small Cell Lung Re Hepatocellular Carcinoma Breast Renal Cell Carcinoma & Gastrointestinal Stromal Tumor Time
Slide 10: Projected 15–20 Submissions 2010–2012
Projected 15–20 Submissions 2010–2012 axitinib – Pancreatic Cancer Zithromax/chloroquine PF-734200 – Diabetes – Malaria S,S-reboxetine PD-200390 – Insomnia – Fibromyalgia PF-299804 – Cancer CP-751871 CP-945598 – Obesity PF-885706 – GERD – 3rd Line NSCLC NMEs PD-332334 – GAD PF-
Slide 11: Steps to Improve Execution
Steps to Improve Execution Focus Resources on Best Identify Winners Early Opportunities Improve Clinical Trial Design to Increase Improve Clinical Probability of a Positive Result Trial Execution Improve Cycle Times
Slide 12: Optimizing the Patent-Protected Portfolio
Optimizing the Patent-Protected Portfolio
Slide 13: Lipitor: Maintaining Leadership Under Intense Competition
Lipitor: Maintaining Leadership Under Intense Competition Lipitor 2007 Worldwide Sales 2008 Focus U.S. Reinforce differentiation with Japan/Asia $7.8B compelling body of clinical $1.5B (+7%) (-6%) and outcomes evidence Canada/ Drive activities targeted at Latin new and continuing patients Americ
Slide 14: Global Lyrica Forward Plan: Differentiate, Grow and Expand
Global Lyrica Forward Plan: Differentiate, Grow and Expand 2007 2008 + Core Indications Strengthen Core and Expand Restless Legs Syndrome Epilepsy Neuropathic Pain Neuropathic GAD Pain Post Op Epilepsy Pain Fibro Fibromyalgia GAD
Slide 15: Celebrex: Preserve Today & Set the Stage for Growth
Celebrex: Preserve Today & Set the Stage for Growth Strengthen Repair the Patient- Optimize Near-Term Understanding of Physician Dialogue Execution Efficacy & Safety Mid-Term Completion of Large Safety Studies (CONDOR, PRECISION)
Slide 16: Chantix: For Smokers Motivated to Quit
Chantix: For Smokers Motivated to Quit 45M Smokers 25M Smokers in the U.S. Motivated to Quit Control Immature Takers Quitters 26% 25% 11.7M Desire to Quit Chantix Target MD/Rx- Defiant Dependent Smokers Quitters 20% 29% 13.0M Openness to Medical Intervention
Slide 17: Sutent: The Bedrock of Our Oncology Portfolio
Sutent: The Bedrock of Our Oncology Portfolio U.S. Potential New Indications mRCC Patient Share – 1st Line Expected to Drive Value 70% 60% CRC 50% 53% es nu 40% ve NSCLC Re 30% HCC Nexavar, 25% 20% BC cytokine, 11% 10% Torisel, 7% RCC / GIST Other, 5% 0% J F M A M J J A S O N D 2007 Time Source: Imp
Slide 18: Key Strategies
5 Key Strategies Refocus and Optimize the Patent- protected Portfolio Instill a Find New Culture of Opportunities Innovation and for Continuous Established Improvement Products Invest in Grow in Complementary Emerging Businesses Markets
Slide 19: The Opportunity
The Opportunity Global Pharmaceutical Sales ($ billions USD) $898 CAGR $576 “Established” $523 11% Market Is: Established Big Products (Near-Post $271 Fast growing LOE) Profitable Innovative $375 4% Products $305 (Pre-LOE) 2006 2012 * Excludes Africa/Middle East market. Source: Datamonitor; Ev
Slide 20: The Market Is Not Homogenous, Three Distinct Market Segments
The Market Is Not Homogenous, Three Distinct Market Segments Branded Emerging Markets Branded Traditional Markets IP-Driven Markets Source: Datamonitor; EvaluatePharma; analyst reports.
Slide 21: Our Competitive Advantage = Value Creation
Our Competitive Advantage = Value Creation Leverage Strengths & Capabilities Our Product Portfolio Strong brand recognition Track record of proven efficacy and safety Become a World Leader Strong book of business today in in Product established products Enhancements and Current portfolio abo
Slide 22: Our Goal – Outpace Market Growth
Our Goal – Outpace Market Growth Increase Emphasis on 1 Our Existing Portfolio Broaden the Geographic 2 Reach of Our Offerings Develop Partnerships 3 to Accelerate Our Pace
Slide 23: Key Strategies
5 Key Strategies Refocus and Optimize the Patent- protected Portfolio Instill a Find New Culture of Opportunities Innovation and for Continuous Established Improvement Products Invest in Grow in Complementary Emerging Businesses Markets
Slide 24: Right Geographies
Right Geographies #2 Europe $13.3B 7.0% Share #1 U.S. #4 Africa/ #1 Japan $25.5B Middle East #1 Asia $3.7B 9.2% Share $0.4B $2.6B 6.4% Share 5.8% Share 5.5% Share #1 Latin America $1.4B 6.1% Share The Powerful Forces of Globalization Play to Our Strength Source: IMS MAT 4Q2007
Slide 25: Right Products
Right Products New In-Line Established (glipizide) Extended Release Tablets Dynastat ® IV/IM (parecoxib sidico injectable)
Slide 26: The Emerging Asian Markets Opportunity
The Emerging Asian Markets Opportunity Today 2012 Projection 2017 Projection 7–9% 6% 4% $47B $79B $111B Market Pfizer Source: Projections based upon IMS Market Prognosis March 2007 & Internal Analysis (excludes Japan, Australia, New Zealand)
Slide 27: Pfizer Well-Positioned and Investing for Growth in Emerging Asian Markets
Pfizer Well-Positioned and Investing for Growth in Emerging Asian Markets Asia Footprint People Significant 2007 Sales Programs to develop and Growth retain talent across markets #1 Rank in Asia Strong cadre of very experienced managers Regional support footprint in Hong Kong with cross-
Slide 28: Capturing Global Advantage – Building Out Today's Presence
Capturing Global Advantage – Building Out Today’s Presence R&D Manufacturing $300 million investment in Manufacturing sites and experience South Korea across Asia R&D facility in China First trigeneration power plant in Establish incubators to aid Asian Singapore – an environmental- start-
Slide 29: Asia Strategy Goals
Asia Strategy Reinforce market leadership in the region, grow market share from 4% to 7–9% #1 pharma company in China, grow market share from ~2% to ~8–11% Goals Drive Korea to $1 billion business Top 3 in fast-growing Asian oncology market Capture global advantage
Slide 30: Right Products, Right Business Models, Right Geographies
Right Products Right Business Models Right Geographies
Slide 31: Key Strategies
5 Key Strategies Refocus and Optimize the Patent- protected Portfolio Instill a Find New Culture of Opportunities Innovation and for Continuous Established Improvement Products Invest in Grow in Complementary Emerging Businesses Markets
Slide 32: Our Path Forward
Our Path Forward Joe Feczko Senior Vice President & Chief Medical Officer
Pfizer — Cowen and Company 28th Annual Health Care Conference (March 2008) on 6ix